Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
KALA BIO, Inc. (NASDAQ: KALA) generates news that spans clinical trial developments, strategic reviews, financing transactions and capital structure changes in the ophthalmology-focused biopharmaceutical space. As a clinical-stage company centered on rare and severe eye diseases, its updates often revolve around the progress and outcomes of its investigational programs and the funding required to support them.
A major theme in recent KALA news has been the development of KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy studied for persistent corneal epithelial defect (PCED). The company has reported on milestones such as completion of enrollment in the CHASE Phase 2b trial and, later, topline results showing that the study did not meet its primary or key secondary endpoints. These disclosures were accompanied by announcements about ceasing development of KPI-012 and the MSC-S platform, workforce reductions and an evaluation of strategic options.
Another significant stream of news involves financing and restructuring. KALA has issued press releases on a registered direct offering of common stock, a securities purchase agreement for non-voting convertible preferred stock, and a convertible loan agreement, as well as updates on a loan settlement with Oxford Finance LLC that resolved substantial debt obligations. Leadership and governance changes, including appointments in executive roles and board positions, have also been reported.
Investors and followers of KALA BIO’s news can expect coverage related to clinical data readouts, regulatory designations, Nasdaq listing compliance matters, debt settlements, equity offerings and strategic transaction discussions. Monitoring this news flow provides context on the company’s evolving pipeline priorities, financial position and potential corporate actions. For an ongoing view of these developments, readers can review the chronological news feed associated with the KALA ticker.
Kala Bio (NASDAQ: KALA) engaged Dr. Saeid Babaei as Senior Scientific Advisor on April 1, 2026 to evaluate clinical and molecular assets, including its MSC Secretome platform, using AI-enabled analytics, digital health tools, and secure data integration to assess responder hypotheses and amended indication opportunities.
The initial work will review Phase 2 datasets, trial protocols, and translational hypotheses to inform development, partnering, licensing, or commercialization pathways.
KALA BIO (NASDAQ: KALA) announced the commercial launch of the Bionic Intelligence Research Agent (BIRA) on March 30, 2026, delivered via the Researgency.ai platform under an exclusive worldwide license with Younet. BIRA runs a 70-billion-parameter model for biotech and pharma research inside VPN-only, client-controlled infrastructure.
The platform targets enterprise security, audit trails, private data sovereignty, and a platform-as-a-service revenue model, and Kala highlighted a near-term roadmap of four agentic features including alerts, IP monitoring, and compressed publication reviews.
Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) engaged Kala Bio's Researgency.ai platform to support clinical development of PEX010, Filament’s patented botanical psilocybin drug candidate. The engagement will deploy agentic AI for clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 following a definitive arrangement to acquire Filament.
PEX010 is supplied to >70 clinical sites, has Health Canada and FDA trial authorizations, and showed positive Phase 2 data in alcohol use disorder; Kala holds exclusive worldwide distribution/development license for Researgency.ai.
Kala Bio (NASDAQ: KALA) rebranded Researgency.ai and says its enterprise AI platform is live, with the company expecting to ship its first commercial AI agent in approximately 14 days. The firm positions Researgency.ai as a secure, auditable OS for biotech agents targeting research, trials, regulatory, safety, and commercial workflows.
Kala frames this move as a shift from a single-drug biotech to a dual-engine company combining an FDA-designated drug pipeline with a scalable AI product aimed at a projected $180+ billion AI-in-healthcare market by 2030.
KALA BIO (NASDAQ: KALA) announced a strategic initiative to deploy an on-premises, data-sovereign AI infrastructure for biotech and an exclusive license to the proprietary Researgency platform for an initial 12-month term.
The platform will be first applied internally to KALA’s MSC-S datasets and KPI-012 program, with external licensing planned after internal validation.
KALA BIO (NASDAQ:KALA) announced it has completed a loan settlement with Oxford Finance, resolving approximately $10.6 million of debt as of December 26, 2025. The company made a $2.0 million payment required under a November 25, 2025 Loan Settlement Agreement, which fully satisfied obligations under the Settlement Agreement and the underlying May 4, 2021 Loan Agreement.
Management said the settlement removes a material overhang and increases strategic flexibility. Separately, on December 30, 2025, the board approved inducement grants totaling 400,000 common shares to four new employees.
KALA BIO (NASDAQ:KALA) closed a registered direct offering on Dec 5, 2025, selling 10,000,000 shares (or pre-funded warrants) at $1.00 per share, generating approximately $10 million in gross proceeds before fees.
The offering was priced at-the-market under Nasdaq rules, used a shelf registration (File No. 333-270263 declared effective May 11, 2023), and named H.C. Wainwright & Co. as exclusive placement agent. The company intends to use net proceeds to repay certain indebtedness and for general corporate purposes. Prospectus materials are available on the SEC website.
KALA BIO (NASDAQ:KALA) entered definitive agreements for a registered direct offering of 10,000,000 shares (or pre-funded warrants) at $1.00 per share, expected to close on or about December 5, 2025. Gross proceeds are expected to be approximately $10 million before placement agent fees and offering expenses. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds to repay certain indebtedness and for general corporate purposes. The securities are offered under a shelf registration (File No. 333-270263) declared effective May 11, 2023; offering materials will be filed with the SEC and available on the SEC website.
KALA BIO (NASDAQ:KALA) entered a $6.0 million securities purchase agreement with investor David E. Lazar on Dec 1, 2025, receiving $1.8 million at the first closing and issuing non-voting convertible Series AA preferred stock. Effective immediately, Mr. Lazar was appointed CEO and Chairman; former CEO Todd Bazemore remains on the board. The company previously announced on Sept 29, 2025 that its CHASE Phase 2b trial of KPI-012 failed the primary endpoint and key secondaries, prompting a temporary development pause. KALA plans to redevelop candidates and pursue a potential strategic transaction; the $4.2 million second closing requires stockholder approval expected in Q1 2026.
KALA BIO (NASDAQ:KALA) announced that its CHASE Phase 2b clinical trial evaluating KPI-012 for persistent corneal epithelial defect (PCED) treatment has failed to meet its primary endpoint of complete PCED healing at Week 8. The trial also did not achieve statistical significance for key secondary efficacy endpoints, showing no meaningful difference between KPI-012 treatment arms and placebo.
As a result, KALA will cease development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform. The company plans to preserve cash through workforce reduction and other cost-saving measures while evaluating strategic options and engaging in discussions with its secured lender.